About Us

Overview

Yumanity Therapeutics is transforming drug discovery for neurodegenerative diseases caused by protein misfolding. Founded in December 2014 by award winning protein folding expert, Susan Lindquist, Ph.D., and renowned biotech industry leader, Tony Coles, M.D., Yumanity Therapeutics is working to identify and develop new, disease-modifying therapies that address several illnesses with critical unmet medical needs. The focus of the privately held company is neurodegenerative diseases, including Alzheimer’s disease, Parkinson’s disease and amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig’s disease. The company’s proprietary platforms have already identified one potential new target for treating Parkinson’s disease, and Yumanity Therapeutics is actively advancing its new chemical lead series for this condition, as well as identifying additional compounds for Alzheimer’s disease and ALS.

Diseases affecting the brain and central nervous system represent one of the largest global healthcare challenges and greatest medical needs due to the devastating personal and economic consequences for patients, caregivers and society. Despite the fact that an estimated 55 million people worldwide suffer from them, there are no approved disease-modifying therapies or cures. As modern therapeutic interventions increase life expectancy, the number of patients suffering from these diseases is expected to double every 20 years.1,2 Global costs for treating these diseases are currently estimated at $818 billion and expected to grow to more than $1 trillion by 2030.1,2,3 Leveraging its three integrated discovery platforms, Yumanity Therapeutics’ new approach to drug discovery and development concentrates on the cell’s characteristics, or phenotype, and the disease pathologies caused by protein misfolding.

Headquartered in Cambridge, MA, Yumanity Therapeutics has assembled a team of experts committed to making a difference in the lives of the millions of people suffering from neurodegenerative diseases. After early robust and positive results, Yumanity Therapeutics raised $45M Series A financing led by Fidelity Management & Research with participation from Redmile Group, Alexandria Venture Investments, Biogen, Sanofi-Genzyme BioVentures and Dolby Family Ventures in February of 2016 to accelerate the discovery and development of novel therapies in neurodegenerative diseases including Alzheimer’s disease, Parkinson’s disease and ALS.

1. UBS, Alzheimer’s Report, July 2014; Industry Research
2. Alzheimer’s Disease International, World Alzheimer Report 2015
3. Parkinson’s Disease Foundation. http://www.pdf.prg/en/parkinson_statistics